BridgeMD
Lepidoglyphus destructor extract. Determination of in vivo allergenic potency in histamine equivalent prick testing units (HEP).
EU CTIS ID: 2023-509541-13-00
What this study is testing
Assessment of the concentration of Lepidoglyphus destructor extract that induces a wheal of size equivalent to that produced by a 10 mg/mL histamine dihydrochloride solution.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Positive medical history of inhalant allergy (rhinitis and/or rhinoconjunctivitis and/or asthma) to Lepidoglyphus destructor.
- A positive prick-test (mean wheal diameter ≥ 3 mm) with an extract of the same allergen and/or presence of specific IgE to the allergen.
- The mean area of the wheal obtained with 10 mg/mL Histamine dihydrochloride should be ≥ 7 mm².
- Age between 18 and 64 years.
- Must be able to provide informed consent.
- * Women of childbearing age (i.e following menarche and until postmenopause, defined as no menses for 12 months without an alternative medical cause, or non-subject to permanent sterilization methods, such as hysterectomy, bilateral salpingectomy and bilateral oophorectomy) must present a negative urine pregnancy test at the time of enrollment in the trial, as well as a confirmed menstrual period.
You likely can't join if
- Subjects outside the age range.
- Pregnant or potentially pregnant women and breastfeeding women.
- Subjects with known phenol allergy.
- Subjects who have previously received immunotherapy within the last 5 years for the treatment of asthma or allergic rhinoconjunctivitis induced by allergens that may interfere with Lepidoglyphus destructor extracts.
- Subjects with significant symptoms of rhinoconjunctivitis and/or bronchial asthma in whom discontinuation of systemic antihistamine treatment is contraindicated.
- Subjects who have previously exhibited a severe adverse reaction during diagnostic skin prick tests.
See the full eligibility criteria
- Positive medical history of inhalant allergy (rhinitis and/or rhinoconjunctivitis and/or asthma) to Lepidoglyphus destructor.
- A positive prick-test (mean wheal diameter ≥ 3 mm) with an extract of the same allergen and/or presence of specific IgE to the allergen.
- The mean area of the wheal obtained with 10 mg/mL Histamine dihydrochloride should be ≥ 7 mm².
- Age between 18 and 64 years.
- Must be able to provide informed consent.
- * Women of childbearing age (i.e following menarche and until postmenopause, defined as no menses for 12 months without an alternative medical cause, or non-subject to permanent sterilization methods, such as hysterectomy, bilateral salpingectomy and bilateral oophorectomy) must present a negative urine pregnancy test at the time of enrollment in the trial, as well as a confirmed menstrual period.
- * Women of childbearing age must commit to using a highly effective and adequate contraception method during the trial and up to 72 hours after the end of treatment with the investigational medicinal product. Such methods include combined (estrogen and progestogen containing) hormonal; contraception associated with inhibition of ovulation (oral, intravaginal or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), intrauterine device, intrauterine hormone-releasing system, male condom, diaphragm used with spermicide, bilateral tubal occlusion, vasectomized partner or sexual abstinence.
- Subjects outside the age range.
- Pregnant or potentially pregnant women and breastfeeding women.
- Subjects with known phenol allergy.
- Subjects who have previously received immunotherapy within the last 5 years for the treatment of asthma or allergic rhinoconjunctivitis induced by allergens that may interfere with Lepidoglyphus destructor extracts.
- Subjects with significant symptoms of rhinoconjunctivitis and/or bronchial asthma in whom discontinuation of systemic antihistamine treatment is contraindicated.
- Subjects who have previously exhibited a severe adverse reaction during diagnostic skin prick tests.
- Subjects on treatment with ß-blockers.
- Clinically unstable subjects (acute asthma, febrile, etc.).
- Subjects with active urticaria lesions, severe active dermographism, severe atopic dermatitis, sunburn, eczema, psoriasis lesions in the area where the prick test is performed (risk of false positives).
- Subjects with active herpes simplex viral infection, or herpes varicella zoster in the area where the prick test is performed.
- States in which the subject is unable to offer cooperation and severe psychiatric disorders.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.